Source: Getty Images Results from the phase 3 TiNivo-2 trial suggest that immune checkpoint inhibitor rechallenge should generally be discouraged in patients with advanced clear cell RCC ...
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...
In patients with advanced clear cell renal cell carcinoma (ccRCC), sitravatinib (tyrosine kinase inhibitor) has shown efficacy both alone and in combination with nivolumab (anti-PD-1). Here ...
Opdivo Qvantig combines nivolumab, a programmed death receptor ... in 495 patients with advanced or metastatic clear cell renal cell carcinoma who received no more than 2 prior systemic therapies.
Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated ...
healthday on MSN1d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast CancerFor patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (H ...
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC ...
Hosted on MSN1mon
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment BrightensA total of 495 patients were randomized to receive either “subcutaneous nivolumab and hyaluronidase ... The approval includes indications for renal cell carcinoma; melanoma; non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback